NASDAQ$CRIS
Curis Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Curis reported a net loss for Q4 2019, discontinued fimepinostat-venetoclax combination study, and prioritized resources for CA-4948 and CI-8993 clinical development programs.
Curis reported a net loss of $8.6 million for the fourth quarter of 2019, compared to a net loss of $5.9 million for the same period in 2018. Revenues for the fourth quarter of 2019 were $3.3 million, compared to $2.8 million for the same period in 2018. The company is prioritizing resources for CA-4948 and CI-8993 clinical development programs and discontinuing the fimepinostat-venetoclax combination study.
- Curis reported a net loss of $8.6 million, or $0.26 per share, for Q4 2019.
- Revenues for Q4 2019 were $3.3 million, primarily from royalty revenues on Erivedge.
- The company discontinued its Phase 1 study of fimepinostat in combination with venetoclax.
- Curis is prioritizing resources for the clinical development programs of CA-4948 and CI-8993.
Headline financials
Revenue & EPS history
Curis · Revenue · Quarterly
$3.29M
Revenue by segment
Curis · $3.23M total across 1 segment · Q4 2019
- Royalties$3.23M+16.6%100.0%
Forward guidance
Curis plans to continue dose escalation of CA-4948 and report updated efficacy data in 2020, initiate a Phase 1 trial of CA-4948 in AML and MDS in the first half of 2020, and initiate a Phase 1a/1b study of CI-8993 in the second half of 2020. The company expects its existing cash, cash equivalents, and investments should enable it to maintain its planned operations into the second half of 2020.
Tailwinds
- Continue dose escalation of CA-4948 in the ongoing Phase 1 study to determine the recommended Phase 2 dose.
- Report updated efficacy data from the CA-4948 study in 2020.
- Initiate a Phase 1 study of CA-4948 in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in the first half of 2020.
- Initiate a Phase 1a/1b dose escalation study of CI-8993 in the second half of 2020.
- Existing cash, cash equivalents, and investments should enable Curis to maintain its planned operations into the second half of 2020.
Headwinds
- Curis may experience adverse results, delays and/or failures in its drug development programs.
- Curis's drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization.
- Curis will require substantial additional capital to fund its business.
- Curis faces substantial competition.
- Unstable market and economic conditions, natural disasters, public health crises, political crises and other events outside of Curis's control could significantly disrupt its operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2019
-1.7%
Avg return
Earnings day
-1.2%
Avg return
5 days after
+14.9%
Avg return
30 days after
37%
23 / 63 earnings
Positive
+46.2%
Q4 2017
Best reaction
-26.3%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.3% | -4.6% | — | |
| Q1 2026 | -9.5% | -13.1% | -23.7% | |
| Q3 2025 | -7.2% | -15.8% | -7.5% | |
| Q4 2024 | -9.5% | -38.6% | -32.4% | |
| Q3 2024 | +0.5% | -3.6% | -9.2% | |
| Q2 2024 | -8.8% | -12.4% | +0.9% | |
| Q1 2024 | +1.1% | -2.8% | -40.2% | |
| Q4 2023 | +10.9% | +8.0% | +11.8% | |
| Q3 2023 | -3.0% | +15.3% | +151.8% | |
| Q2 2023 | -11.5% | -17.7% | -26.6% | |
| Q1 2023 | -0.6% | +2.5% | +6.2% | |
| Q4 2022 | -10.9% | -14.3% | +31.7% | |
| Q3 2022 | +5.1% | +15.4% | -1.3% | |
| Q2 2022 | +2.0% | +0.0% | -7.1% | |
| Q1 2022 | -12.6% | +2.0% | -6.0% | |
| Q4 2021 | +9.2% | +15.7% | -15.4% | |
| Q3 2021 | -0.7% | -2.5% | -21.1% | |
| Q2 2021 | -6.9% | -10.1% | +13.9% | |
| Q1 2021 | +33.0% | +53.1% | -18.5% | |
| Q4 2020 | -1.7% | +10.2% | +10.8% | |
| Q3 2020 | +12.0% | +13.9% | +647.2% | |
| Q2 2020 | +16.8% | +19.3% | -16.0% | |
| Q1 2020 | -12.0% | -10.5% | +55.8% | |
| Q4 2019 | -7.1% | -4.2% | +9.7% | |
| Q3 2019 | -26.3% | -39.1% | -24.3% | |
| Q2 2019 | -21.3% | -20.9% | -18.3% | |
| Q1 2019 | -1.6% | -11.4% | -22.7% | |
| Q4 2018 | +5.8% | +5.3% | -5.8% | |
| Q3 2018 | +5.5% | -1.8% | -47.2% | |
| Q2 2018 | -9.8% | -12.4% | -12.4% | |
| Q1 2018 | -10.8% | -12.5% | -11.1% | |
| Q4 2017 | +46.2% | +43.9% | -5.3% | |
| Q3 2017 | -11.3% | -18.5% | -44.4% | |
| Q2 2017 | +0.0% | -1.2% | +21.5% | |
| Q1 2017 | -11.7% | -7.9% | -10.7% | |
| Q4 2016 | +16.1% | +12.5% | +2.0% | |
| Q3 2016 | -3.6% | +11.1% | +20.2% | |
| Q2 2016 | -1.7% | +1.1% | -3.4% | |
| Q1 2016 | +7.3% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | -9.7% | — | — | |
| Q1 2015 | +4.6% | — | — | |
| Q4 2014 | +0.3% | — | — | |
| Q3 2014 | -0.8% | — | — | |
| Q2 2014 | -7.8% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +11.4% | — | — | |
| Q3 2013 | -25.2% | — | — | |
| Q2 2013 | +3.0% | — | — | |
| Q1 2013 | -9.4% | — | — | |
| Q4 2012 | -4.0% | — | — | |
| Q3 2012 | -3.4% | — | — | |
| Q2 2012 | -0.9% | — | — | |
| Q1 2011 | +2.9% | — | — | |
| Q1 2012 | +0.6% | — | — | |
| Q4 2011 | -1.9% | — | — | |
| Q3 2011 | -6.8% | — | — | |
| Q3 2010 | -6.8% | — | — | |
| Q2 2011 | -10.6% | — | — | |
| Q2 2010 | -10.6% | — | — | |
| Q4 2010 | +2.4% | — | — | |
| Q1 2010 | -6.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro